Ramon Mohanlal, M.D., Ph.D.

EVP, Research and Development, Chief Medical Officer

Dr. Mohanlal has more than 20 years of global experience in strategic drug development at big pharma, and biotech start-ups, including GlaxoWellcome (GSK), Pharmacia (Pfizer), Vertex,Interleukin Genetics, Syntium, Novartis, and AstraZeneca. His expertise includes drug development in all Phases (preclinical and 1, 2, 3, 4 clinical, post-marketing), regulatory filings and maintaining drugs on the market.

Dr. Mohanlal played a crucial role in bringing five drugs to market and was deeply involved in the development of 15 marketed drugs, including Wellferon, Atovaquone, Lamuvidine, Zomig, Advexin, Abilify IM Depot, Zometa, Femara, Aredia, Proleukin, Cardioxane and Exjade.  Most recently, Dr. Mohanlal was the Clinical Head of Established Oncology Products for Novartis, where he managed all clinical and regulatory maintenance work for the division, which represented total annual revenue of approximately $2 billion. He also developed immuno-oncology development programs based on checkpoint inhibitor combination therapy at AstraZeneca. Prior to this, Dr. Mohanlal held positions with Interleukin Genetics as Chief Medical Officer and Vertex Pharmaceuticals as Medical Director. Dr. Mohanlal has also obtained extensive licensing and deal-making experience at Syntium Inc.

Dr. Mohanlal earned his M.D. and Ph.D. in Experimental CV Pharmacology, both from the University of Leiden, The Netherlands, as well as his M.B.A. from the American Intercontinental University in Illinois, with post-graduate business training at the MIT Sloan School of Management, Cambridge, Massachusetts.

© 2020 BeyondSpring Inc. All rights reserved.